SynthesisChina CDC weekly2022
Interpretation of the National Action Plan for Eliminating Hepatitis C as a Public Health Threat (2021-2030).
Synthesis in China CDC weekly, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cancer burden and control in China: landscape, trends and challenges.Nature reviews. Clinical oncology · 2026Review
- [Analysis of epidemiological characteristics and spatial clustering of hepatitis C virus in China from 2018 to 2022].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Interpretation of China's Action Plan for Viral Hepatitis Prevention and Care (2025-2030).China CDC weekly · 2026Article
- Evaluations of Community-based Healthcare Management for Patients with Chronic Viral Hepatitis - Shanghai Municipality, China, 2012-2023.China CDC weekly · 2025Article
- The macroeconomic burden of hepatitis C and the economic benefit of accelerated investments in China.BMC public health · 2025Article
- Transmission network of Hepatitis C virus subtype 2a in Huazhou County, Shaanxi Province, China.BMC infectious diseases · 2024Article
- Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis.JHEP reports : innovation in hepatology · 2024Article
- Hepatitis C Knowledge and Self-Reported Testing Behavior in the General Population in China: Online Cross-Sectional Survey.JMIR public health and surveillance · 2023Article
- Multi-disciplinary cooperation for the micro-elimination of hepatitis C in China: a hospital-based experience.BMC gastroenterology · 2023Article
- Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV - Guangxi Zhuang Autonomous Region, China, 2003-2022.China CDC weekly · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection is a major public health problem in China. In 2016, the World Health Organization (WHO) proposed a goal to eliminate viral hepatitis as a public health threat by 2030, and in 2018, the National Health Commission of China launched Hepatitis C Elimination Action by 2030. Hepatitis C control and prevention has made significant progress in China in recent years. To implement the "Healthy China 2030" plan and the Healthy China Initiative (2019-2030), and to contribute to the global target of eliminating viral hepatitis as a public health threat by 2030, the National Health Commission of China and eight other government departments jointly issued the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.